In medical terminology, a bolus is a massive dose of a drug administered all at once. Jazz Pharmaceuticals has experienced a similar infusion of cash recently, thanks in large part to the success of its narcolepsy drug, Xyrem, which improves the quality of narcoleptics’ waking hours by helping them get a good night’s sleep.

With no market competition for Xyrem, the Dublin-based biopharmaceutical has been able to ratchet up its price twice this year. Acquisitions of Azur Pharma and EUSA Pharma in 2012 are also adding sales and reducing the company’s reliance on Xyrem. With EUSA, Jazz brought in Erwinaze, now the second-highest seller in its ensemble. The leukemia drug contributed more than 20% of the company’s first quarter revenue. --Shannon Green